Simulations Plus, Inc.

Model-based meta analysis (MBMA) informs key drug development decisions by integrating data, published or unpublished, from multiple studies. Due to these various sources of information and large number of individuals, MBMA models require careful implementation, and this webinar will show you how to do it. Join us for this this webinar to learn how to develop MBMA models from summary-level longitudinal data (e.g., mean responses over treatment arms), how to include between-study variability and between-treatment-arm variability, and how to apply appropriate weighting with Monolix. You’ll learn how to use this model in Simulx for decision support by simulating a clinical trial while accounting for variability in parameter estimates. With the step-by-step presentation of two case studies, you will discover practical applications of MonolixSuite to support model-informed drug development (MIDD). Register now! https://lnkd.in/g63jR-MC

Are you a nonprogrammer looking to expand your skills? ? Join Senior Principal Scientist, Michael Lawless at the SOT 64th Annual Metting and ToxExpo for a continuing education course “Ready, Steady, PBK Model – Leveraging Machine Learning to Jump Start Your Simulations” on Sunday March 16 for part of the afternoon session ?titled, "Physiologically Based Kinetic Modeling Made Simple: A Nonprogrammer’s Guide to Chemical Risk Assessment."? https://lnkd.in/gmX-92fN?

AI is reshaping the landscape of drug discovery and scientific research—and in a recent podcast with Bioanalysis Zone, Dr. Priyata Kalra, Senior Scientist, discusses how that creates powerful opportunities for researchers like you. Listen here: https://lnkd.in/eFQZf-r9

In a recent study, researchers wanted to learn whether sustained supersaturation generated from amorphous solid dispersions (ASDs) formulated in insoluble hydrogel carriers would result in better bioavailability over that of spring-and-parachute type of dissolution profiles of ASDs formulated in water-soluble carriers. They used GastroPlus? 9.7 to evaluate in vivo dissolution and absorption characteristics of Fenofibrate from these ASDs. https://lnkd.in/gp98Duum

Have you wondered about the differences between PBPK and PBBM? These two powerful modeling approaches play distinct roles in drug development, and understanding their applications can make a difference in your research and regulatory strategy. Learn more about PBPK and PBBM and when to use each in this new blog post from Frederico Martins: https://lnkd.in/g58nnZJx

We’re excited to announce that registration is now open for the Introductory Population PK Training Workshop, offered in collaboration with the University of Buffalo! This is your chance to learn population PK modeling from renowned industry experts Jill Fiedler-Kelly. Through live lectures, hands-on exercises, and group activities, you’ll gain practical skills, experience, and insights. This in-person course often sells out, so register now! Learn more: https://lnkd.in/grGXNkyP

Due to overwhelming demand, MIDD+ is returning to Utrecht, Netherlands, this March 11-12. This is your opportunity to learn from industry experts and dive deep into advancements in Model-Informed Drug Development (MIDD). Mark your calendars for this in-person event. Spaces are limited—register today to secure your spot and boost your skills! https://lnkd.in/g4cGH3c5

Understanding and predicting drug-drug interactions (DDIs) is crucial for ensuring patient safety and improving drug product development strategies. Not all pathways are created equally, however – the cytochrome P450 (CYP) enzyme family metabolizes the majority of marketed drugs, with many compounds also acting as perpetrators, making them a major source of clinically relevant DDIs. Join Dr. Viera Lukacova (Chief Science Officer, PBPK/CHEM Solutions) and Dr. Xinyuan (Susie) Zhang (Vice President, Regulatory Strategies) for this webinar as they outline a reliable, mechanistic PBPK modeling framework for predicting CYP enzyme-mediated DDIs with a high degree of confidence. Specifically, this webinar will provide practical strategies to help you identify, evaluate, and mitigate potential DDIs through modeling & simulation, ultimately ensuring drug product safety and supporting its regulatory approval. What you will learn: 1. How to apply and interpret regulatory guidance and decision trees for evaluating CYP-mediated DDIs 2. The latest advancements using in vitro data and in silico tools for DDI prediction 3. Identification and integration of key clinical pharmacology information, including DDI data for more accurate risk assessment 4. The importance of high-quality DDI standard models and reports in providing validated, regulatory-aligned solutions Register now to secure your spot! https://lnkd.in/gRCQGPG8

If you’ll be at the SOT 64th Annual Meeting & ToxExpo next month, you won’t want to miss this presentation. Brunch & Learn: Recent Advances in Predicting Drug-Induced Liver Injury (DILI) by Scott Siler, Ph.D. – Mar 19, 9:15-10:15 AM (Room W208C) And of course, be sure to stop by booth #1327 to say hello to our team!

Meet Lenore. She’s a 62-year-old woman with a history of type 2 diabetes, hypertension, and new onset heart failure. She’s also a simulated patient in an adaptive learning program that helped identify and address gaps in clinician understanding about type 2 diabetes treatment strategies. Learn more about how we helped our client—with Lenore—to improve their training and clinicians’ skills. https://lnkd.in/gZwXUt_g